Introduction
For decades, antiplatelet therapy has been the mainstay of therapy for the prevention of cardiovascular disease (CVD). Aspirin is the antiplatelet drug of choice and has well documented benefits in secondary CVD prevention. The use of aspirin for primary prevention remains controversial due to conflicting results from clinical trials and meta-analyses. 1e5 A variety of national organizations provide guidance on utilizing aspirin for primary CVD prevention. 6e13 Historically, these guidelines have provided a favorable recommendation for using aspirin, although more recently there is growing controversy surrounding aspirin for this indication.
There are limited data for primary CVD prevention specifically for geriatric patients with diabetes. In the USA, it is estimated that more than 10 million people older than 65 years have diabetes, which includes almost 27% of all people in the geriatric age group. 14 Geriatric patients with diabetes are at high risk for CVD events such as myocardial infarction and stroke. Treatment with aspirin may provide a protective benefit. However, increasing age also increases the risk for adverse events associated with daily aspirin therapy, such as bleeding. There is a fine balance between the risks and benefits of aspirin for primary CVD prevention in geriatric patients with diabetes. Both the American Diabetes Association (ADA) and the American Geriatrics Association (AGS) have published guidelines on the care of patients with diabetes that include recommendations on the use of aspirin. 6, 7 The ADA guidelines recommend aspirin for primary prevention if the patient's 10-year CVD risk score is ! 10%. 6 The AGS states that aspirin for primary CVD prevention is not recommended for patients ! 65 years with diabetes. 7 As a result of different guideline recommendations, providers caring for geriatric patients with diabetes may have differing prescribing patterns. Our hypothesis was that these recommendations might produce greater uncertainty in trainees than established practitioners. Thus, the purposes of this study were: (1) to identify preferences in prescribing of aspirin for primary CVD prevention in geriatric patients with diabetes according to practitioner experience; and (2) to determine how current prescribing patterns compare with the ADA and AGS guidelines.
Methods
The study was approved by the Investigational Review Board at Wayne State University, Detroit, MI, USA and was conducted at various outpatient clinics and inpatient sites within the Detroit Medical Center (DMC; Detroit, MI, USA). Our experienced practitioner group consisted of attending physicians and midlevel providers (nurse practitioners) at the DMC. The trainee group consisted of residents and fellows enrolled in United States-accredited graduate medical education training programs at the DMC.
We created a survey to assess provider preferences on prescribing aspirin for primary CVD prevention in elderly patients with diabetes. Surveys were distributed to providers at staff meetings and small group educational meetings. The following specialties were surveyed: cardiology, endocrinology, geriatrics, and internal medicine. At the beginning of the study, surveys were distributed to attending physicians, fellows and residents, and mid-level practitioners. Surveys were also distributed to internal medicine resident physicians at the end of their rotations.
The following case was given to providers taking the survey. A 68-year-old white woman (MB) is in your office for follow-up of her chronic medical conditions. She has hypertension, hyperlipidemia, and type 2 diabetes mellitus. She has a family history of hypertension (mother and father) and type 2 diabetes mellitus (father). The patient is independent at home and her physical activity is walking her dog. She denies the use of tobacco, alcohol, and illicit drugs. Currently she is taking guideline recommended medications to manage her comorbidities. Her blood pressure, lipids, and diabetes are at goal.
The survey was estimated to take 5e10 minutes. There were a total of 15 questions in a combination of multiple-choice and freetext formats. The survey consisted of two components: (1) five questions pertaining to demographics of the providers and (2) a patient case with 10 clinical questions related to the case. These questions allowed three possible answers; yes, no, or uncertain.
Analysis was performed using nonparametric testing of the following: aspirin prescribing patterns between physicians and mid-level practitioners versus trainees. Chi-square analyses or Fisher exact tests (cell-size dependent) were used to compare categorical variables. For presentation of the results, we combined the no and uncertain answers, thus 2 Â 2 contingency tables were analyzed.
Results
There was 100% response rate with a total of 48 providers who completed the survey. Attending physicians (29.2%) practiced in internal medicine (4.2%), geriatrics (12.5%), cardiology (8.3%), and endocrinology (4.2%). Trainee specialties were all internal medicine residents (58.3%) on rotation for one of the above specialties, or geriatrics fellows (8.3%). Midlevel practitioners were nurse practitioners in geriatrics (4.2%). Responses to all questions were not mandatory, thus response rates to survey questions differed ( Table 1) .
Most providers (42 of 48; 88%) indicated that they would prescribe aspirin for primary CVD prevention in a geriatric patient with diabetes ( Table 2 ). However, only trainees indicated that they would not give aspirin or were uncertain. Of the respondents who chose to give aspirin, all indicated that a dose of 81 mg was preferred. The providers were asked to indicate reasons to give or not give aspirin. Most of them selected age (86%) and comorbidities (98%) as the rationale behind their decision. Others chose sex, race, family, bleeding history, and lifestyle as their reasoning. A majority of respondents indicated they would prescribe aspirin if the patient met any of the following criteria: elevated blood pressure (98%), elevated LDL (92%), elevated A1C (100%), smoking (98%), or male sex (100%). There were no differences in experience-related aspirin treatment recommendations for these criteria.
Responses varied between providers if there was a history of gastrointestinal ulceration and bleeding (overall, 50% yes), and if the patient's age increased over 68 years old (overall, 77% yes if age 75 years and 48% yes if age 85 years). Furthermore, in the case of prior gastrointestinal bleeding, there was evidence that prescribing patterns differed: more trainees recommended aspirin (p ¼ 0.01). Although there was no evidence from the 2 Â 2 contingency table analysis for a difference in the experience-related prescribing pattern based on patient age (Table 2) , there was weak evidence within both groups that aspirin recommendations decreased as age increased from 75 years to 85 years; experienced providers p ¼ 0.08; trainees p ¼ 0.06.
Discussion
We identified through a self-reported survey that most providers would give aspirin for primary CVD prevention. There is limited evidence supporting or refuting the practice of prescribing aspirin for primary CVD prevention in patients with diabetes, especially in the elderly. As of 2013, the AGS guidelines recommend against the use of aspirin in patients with diabetes who are 65 years of age and older. 7 Alternatively, the ADA guidelines recommend prescribing aspirin based on the 10-year CVD risk score. 6 Therefore, current practice guidelines for this population provide conflicting recommendations.
In our survey case, the patient is 68 years and her CVD risk score is 4%. Therefore, both guidelines would recommend against the use of aspirin for the following reasons: the patient is older than 65 years, and CVD risk score is < 5%. However, 88% of respondents indicated that they would prescribe aspirin. These findings suggest that providers do not necessarily follow the AGS and ADA guidelines when making clinical decisions for aspirin therapy in geriatric patients with diabetes.
We found a uniform response from both groups for aspirin use for increased blood pressure, lipid and A1C levels, smoking history, and sex with an overall recommendation rate between 92% and 100%. Conversely, prescribing patterns varied between groups when a medical history of gastrointestinal ulceration and bleeding was present. Attending and midlevel practitioners were more conservative, and less likely to prescribe aspirin to such patients, whereas trainees were more likely to give aspirin. A potential reason for this finding is that attending physicians and midlevel practitioners are more critical of the risks versus benefits of aspirin and have more clinical experience.
We did find, for both groups, a reduction in those recommending aspirin as age increased. The Beers criteria for potentially inappropriate therapy in older adults recommends against the use of aspirin for primary prevention in octogenarians. 9 There are both benefits and risks of daily aspirin therapy for primary CVD prevention. Aspirin increases bleeding risk by inhibiting gastroprotective prostaglandins. By contrast, aspirin offers protection against CVD events by reducing platelet aggregation, activation, and vasoconstriction. This leads to a lower risk of events, which are more commonly seen in elderly patients with diabetes. 15 A patient-specific assessment must be performed and therapy should be tailored based on the patient's age, CVD risk score, and bleeding risk. We recognize that our study has limitations. First, the sample size is small and includes providers from only one geographic area. Therefore, responses may have been influenced by similar practice patterns. Second, the small sample size prevented us from examining whether specialty training influenced the responses; for example, it is possible that those trained in geriatric medicine might have provided response more in line with the guidelines. Third, the survey given was based on a specific case scenario. Hence, the findings may not be generalized across other scenarios, because different cases could elicit different responses from the same providers.
Our findings highlight differences between practice and guidelines. We propose that practitioners should receive more education regarding the risks associated with aspirin therapy in the geriatric population. The current literature is conflicting and prescribing patterns appear inconsistent. More studies are warranted to better guide decision making in primary CVD prevention, especially in the vulnerable elderly.
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